Researchers take a fresh look at hallucinogens

For decades the study of the therapeutic potential of hallucinogens had been badly discredited by the outsized claims made by researchers back in the 1960s. But new research has highlighted the potential therapeutic value of hallucinogens like the mushroom psilocybin for treating depression in cancer victims, post-traumatic stress disorder, obsessive-compulsive disorder, addiction, end-of-life stress and more. Subjects have described intense spiritual experiences similar to religious mystics. Article

Suggested Articles

Levo Therapeutics’ lead program did not beat placebo in a phase 3 study of Prader-Willi syndrome, a genetic disorder that causes insatiable hunger.

Denali is partnering with Biogen on its Parkinson's disease program, netting a $560 million upfront fee and a $465 million investment.

In the first half of 2020, the regenerative medicine sector raised $10.7 billion, more than the total it raised in 2019.